Sugi Predict

Sugi Predict / Compounds / SCHEMBL478732

SCHEMBL478732

SCHEMBL478732

CC(C)(C)OC(=O)N[C@@H](Cc1cscn1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.53
▸ ITGB3 P05106 1/20 0.47
▸ ITGA2B P08514 1/20 0.47
▸ ACE P12821 1/20 0.47
▸ CTSS P25774 3/20 0.45
▸ CTSK P43235 2/20 0.45
▸ FOLH1 Q04609 1/20 0.44
▸ PTPN1 P18031 3/20 0.43
▸ PPARA Q07869 7/20 0.43
▸ PPARG P37231 6/20 0.43
▸ ITGA4 P13612 1/20 0.41
▸ ITGB7 P26010 1/20 0.41
▸ PPARD Q03181 2/20 0.41
▸ CTSL P07711 1/20 0.41
▸ CTSB P07858 1/20 0.41
▸ CAPN1 P07384 1/20 0.40
▸ IDO1 P14902 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL478735 1.00 SCN9A (0.53) SCN9AITGB3ITGA2BACECTSS
SCHEMBL5717580 1.00 SCN9A (0.53) SCN9AITGB3ITGA2BACECTSS
Hydrochloric Acid SCHEMBL28584085 0.99 SCN9A (0.52) SCN9AITGB3ITGA2BACECTSS
SCHEMBL23324594 0.89 SCN9A (0.50) SCN9AITGB3ITGA2BACECTSS
SCHEMBL25888951 0.89 SCN9A (0.50) SCN9AITGB3ITGA2BACECTSS
SCHEMBL6161903 0.88 SCN9A (0.54) SCN9ACTSSCTSKCTSLCTSB
SCHEMBL6161893 0.88 SCN9A (0.54) SCN9ACTSSCTSKCTSLCTSB
SCHEMBL756368 0.87 FOLH1 (0.47) SCN9ACTSSCTSKFOLH1ITGA4
SCHEMBL18731295 0.87 FOLH1 (0.47) SCN9ACTSSCTSKFOLH1ITGA4
SCHEMBL6162648 0.86 SCN9A (0.51) SCN9AITGB3ITGA2BACECTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415835-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-16 — — US disclosed
CN-119752820-A Bioreactive compositions and methods of use thereof 加利福尼亚大学董事会 2025-04-04 — — CN disclosed
CN-119731211-A Cross-linked multispecific antibodies 恩拉扎治疗公司 2025-03-28 — — CN disclosed
US-20250101465-A1 ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF CITY OF HOPE 2025-03-27 — — US disclosed
US-20250074904-A1 NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-03-06 — — US disclosed
CN-119136842-A Cyclodextrin complexes that specialize in resolution mediators 西蒂斯制药有限责任公司 2024-12-13 — — CN disclosed
CN-118922209-A Cross-linked antibodies 恩拉扎治疗公司 2024-11-08 — — CN disclosed
US-20240262791-A1 BIOREACTIVE PROTEINS CONTAINING UNNATURAL AMINO ACIDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-08-08 — — US disclosed
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-23 — — US disclosed
US-11952352-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2024-04-09 — — US disclosed
US-5182266-A Method for treating renal disease ABBOTT LABORATORIES (US) 1993-01-26 — — US disclosed
US-5178877-A Cardiovascular disorders ABBOTT LABORATORIES (US) 1993-01-12 — — US disclosed
US-5122514-A Administering renin inhibitor ABBOTT LABORATORIES (US) 1992-06-16 — — US disclosed
EP-0456185-A2 Renin inhibitors ABBOTT LABORATORIES (US) 1991-11-13 — — EP disclosed
US-5063208-A Cardiovascular disorders, vision defects ABBOTT LABORATORIES (US) 1991-11-05 — — US disclosed
WO-1991016031-A1 PSORIASIS TREATMENT ABBOTT LABORATORIES (US) 1991-10-31 — — WO disclosed
EP-0440102-A1 Method for treating renal disease ABBOTT LABORATORIES (US) 1991-08-07 — — EP disclosed
EP-0410260-A2 Peptidyl aminodiol renin inhibitors ABBOTT LABORATORIES (US) 1991-01-30 — — EP disclosed
EP-0326364-A2 Renin inhibitory oligopeptides, their preparation and use Sankyo Company Limited (JP) 1989-08-02 — — EP disclosed
EP-0274259-A2 New renin-inhibitory oligopeptides, their preparaton and their use Sankyo Company Limited (JP) 1988-07-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240262791-A1 BIOREACTIVE PROTEINS CONTAINING UNNATURAL AMINO ACIDS FRK, DEK, BLK SCN9A 2872/4885ITGB3 2983/4885ITGA2B 2144/4885
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R SCN9A 3795/4885ITGB3 4288/4885ITGA2B 4447/4885
US-20250074904-A1 NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF NCOR2, NSD2, NCOR1 SCN9A 4485/4885ITGB3 4726/4885ITGA2B 4386/4885
US-20250101465-A1 ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF F8, ACTR8, ZCCHC8 SCN9A 1705/4885ITGB3 3659/4885ITGA2B 2266/4885
US-12415835-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R SCN9A 3795/4885ITGB3 4288/4885ITGA2B 4447/4885
US-11952352-B2 Ras inhibitors KRAS, NRAS, HRAS SCN9A 3327/4885ITGB3 3155/4885ITGA2B 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.